Tag:
Benlysta
Latest Headlines
Latest Headlines
GSK tweaks Human Genome bid to include poison pill antidote
The two companies are at loggerheads over a deal. HGS says that Glaxo simply waited until its share price hit rock bottom before offering a bargain basement price for the maker of Benlysta. GSK says it's being more than fair.
Glaxo goes hostile on HGS with $2.6B bid
Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.
GSK raises fists in $2.6B hostile bid for Human Genome Sciences
The gloves are off. GlaxoSmithKline has mounted a hostile offer for its long-time partner Human Genome Sciences.
German gatekeepers nix GSK's lupus drug Benlysta
Germany's new, tougher reimbursement regime has given Benlysta another thumbs-down.
HGS snubs $2.6B buyout offer from Benlysta partner GSK
Human Genome Sciences ($HGSI) is entertaining bids after rebuffing partner GlaxoSmithKline's ($GSK) $2.59 billion buyout overture.
UPDATED: GSK puts Human Genome Sciences in play with $2.59B buyout offer
In moments speculators bid up HGS's battered share value by 110%, to more than $15, as HGS quickly rejected the offer.
It's final: Tasigna in, Sprycel out in NICE guidelines
The National Institute for Health and Clinical Excellence has struck again. Despite two appeals of its draft recommendations, the agency let in only one new drug for chronic myeloid leukemia.
HGS to ax 150 as Benlysta sales continue to disappoint
With its share price battered by disappointing initial sales of the pioneering lupus drug Benlysta , Human Genome Sciences CEO Tom Watkins ( $HGSI ) was preparing to take the stage at the annual JP...
The trials and tribulations of drug launches
Anytime a drugmaker launches a new product--especially a highly touted potential blockbuster--it risks disappointment. The list of drugs introduced with a bang only to see sales whimper is long and
Citi slashes Human Genome target on slow Benlysta sales
Doctors aren't flocking to Benlysta, the new lupus treatment developed by Human Genome Sciences ( $HGSI ) and marketed in partnership with GlaxoSmithKline ( $GSK ), Citi analyst Dr. Yaron Werber says in
